What We Saw at the LNP Analytical Meeting in 2025?
Curated in collaboration with leading analytical experts and key LNP stakeholders, the 3rd LNP Characterization & Analytical Development Summit was a forum focused on advancing LNP analytics and characterization to deliver high-quality, efficacious LNPs to patients in need.
Joining more than 90 experts in analytics, assays, characterization, and CMC for three comprehensive days of in-depth discussions and data-driven presentations. Together, they defined robust analytical strategies to support regulatory submissions and accelerate the development of genomic medicines.
I see great value in attending the LNP Characterization & Analytical Development Summit. This event offers an excellent opportunity to collaborate with experts, discuss innovative techniques, and tackle challenges in LNP stability, efficacy, and regulatory submissions. By participating, I aim to share knowledge, gain insights, and contribute to driving progress in LNP characterization to support the development of genetic medicine.
Jikang Wu, Senior Principal Scientist, Regeneron
2025 Unmissable Agenda Highlights:
Overcome
Overcome the limitations of gold standard QC release assays by leveraging orthogonal techniques for more accurate LNP analysis, with insights from Pfizer and GSK
Uncover
Uncover robust analytical strategies for characterizing and separating multivalent LNPs to accelerate approval of LNP-mediated gene editing medicines, with insights from Novo Nordisk, Sanofi and Prime Medicine
Gain
Gain insights into innovative, advanced assays for targeted LNPs to enable precise understanding of surface functionalization and LNP composition, with insights from Mote Therapeutics and Tessera Therapeutics
Leverage
Levergae advanced imaging methods, such as SAXS and cryo-EM, to evaluate LNP morphology and potency for improving LNP delivery performance, with insights from Pfizer and Suzhou Abogen Biosciences
Align
LNP analytical insights with process performance to advance more LNP drug products from R&D to CMC and towards regulatory approval, with insights from Takeda, Beam Therapeutics and GSK
Explore the Agenda
Experience a jam-packed agenda featuring the latest analytical advancements for targeted and multivalent LNPs, along with exclusive insights into cutting-edge characterization strategies for evaluating LNP size, morphology, and biodistribution
Partner With Us
Position yourself alongside other leading analytical and assay solution providers to ensure your brand is at the heart of LNP deals and collaborations
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all a wide variety of analytical strategies for advancing LNP drug products, and make critical connections during our dedicated networking sessions